- 1.Early recurrence after liver resection (LR) for patients with hepatocellular carcinoma (HCC) carries a poor prognosis.
- 2.We have developed a simple nomogram with preoperative image tumor characteristics and alpha-fetoprotein (AFP) levels to predict the early recurrence of HCC after LR.
To assess preoperative image tumor characteristics and alpha-fetoprotein (AFP) levels to predict early recurrence after liver resection (LR) for hepatocellular carcinoma (HCC).
This retrospective study's enrolled patients underwent LR for newly diagnosed HCC between 2011 and 2018. Multivariate logistic regression analyses using the Akaike information criterion were adopted to construct a nomogram to predict early recurrence (i.e. recurrence within 1 year). The performance of this nomogram was evaluated using calibration plots with bootstrapping.
Early recurrence was identified in 99 patients (11.2%). Four predictive factors, namely an AFP level of >400 ng/mL; image-diagnosed tumor characteristics, including a tumor size of > 5 cm; vascular invasion; and multiple tumors were adopted in the final model of the early recurrence nomogram, with a concordance index of 0.67. The calibration plots showed good agreement between the nomogram predictions and the actual observations of early recurrence.
We have developed a simple nomogram with preoperative image tumor characteristics and AFP levels to predict the early recurrence of HCC after LR.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to The American Journal of Surgery
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Management of hepatocellular carcinoma.J Hepatol. 2018; 69: 182-236https://doi.org/10.1016/j.jhep.2018.03.019
- Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases.Hepatology. 2018; 68: 723-750https://doi.org/10.1002/hep.29913
- Liver.in: Amin M.B. AJCC Cancer Staging Manual. eighth ed. AJCC, Chicago2017: 287
- Prognosis of hepatocellular carcinoma: the BCLC staging classification.Semin Liver Dis. 1999; 19: 329-338https://doi.org/10.1055/s-2007-1007122
- Recurrence patterns and outcomes after resection of hepatocellular carcinoma within and beyond the Barcelona clinic liver cancer criteria.Ann Surg Oncol. 2020; 27: 2321-2331https://doi.org/10.1245/s10434-020-08452-3
- Liver resection of hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guideline recommendations: results from a high-volume liver surgery center in East Asia.J Surg Oncol. 2020; 122: 1587-1594https://doi.org/10.1002/jso.26183
- The impact of portal vein tumor thrombus on long-term survival after liver resection for primary hepatic malignancy.HPB. 2020; 22: 1025-1033https://doi.org/10.1016/j.hpb.2019.10.2439
- Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion.J Hepatol. 2016; 65: 938-943https://doi.org/10.1016/j.jhep.2016.05.044
- Recurrence rate and overall survival of operated ruptured hepatocellular carcinomas.Eur J Gastroenterol Hepatol. 2018; 30: 792-796https://doi.org/10.1097/MEG.0000000000001115
- An analysis of surgical treatment for the spontaneous rupture of hepatocellular carcinoma.Dig Surg. 2016; 33: 43-50https://doi.org/10.1159/000441531
- Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.Cancer. 1954; 7: 462-503https://doi.org/10.1002/1097-0142(195405)7:3<462::aid-cncr2820070308>3.0.co;2-e
- Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial.Hepatology. 2010; 51: 585-594https://doi.org/10.1002/hep.23315
- Byrd D.R. Compton C.C. American Joint Committee on Cancer Staging Manual. seventh ed. Springer, New York2010: 175
- NCCN clinical practice guidelines in oncology: hepatobiliary cancers.J Natl Compr Canc Netw. 2009; 7: 350-391https://doi.org/10.6004/jnccn.2009.0027
- EASL-EORTC clinical practice guidelines management of hepatocellular carcinoma.J Hepatol. 2012; 56: 908-943https://doi.org/10.1016/j.jhep.2011.12.001
- Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma.Hepatol Int. 2010; 4: 439-474https://doi.org/10.1007/s12072-010-9165-7
- Management of hepatocellular carcinoma: an update.Hepatology. 2011; 53: 1020-1022https://doi.org/10.1002/hep.24199
- A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators.Hepatology. 1998; 28: 751-755https://doi.org/10.1002/hep.510280322
- Nomograms predicting extra- and early intrahepatic recurrence after hepatic resection of hepatocellular carcinoma.Surgery. 2021; 169: 922-928https://doi.org/10.1016/j.surg.2020.10.012
- Models to predict disease-free survival for hepatocellular carcinoma patients with surgical resections.J Surg Oncol. 2020; 122: 1444-1452https://doi.org/10.1002/jso.26169
- Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection.J Hepatol. 2018; 69: 1284-1293https://doi.org/10.1016/j.jhep.2018.08.027
- A simplified prediction model for early intrahepatic recurrence after hepatectomy for patients with unilobar hepatocellular carcinoma without macroscopic vascular invasion: an implication for adjuvant therapy and postoperative surveillance.Surg Oncol. 2019; 30: 6-12https://doi.org/10.1016/j.suronc.2019.05.017
- Prediction of hepatocellular carcinoma recurrence beyond milan criteria after resection: validation of a clinical risk score in an international cohort.Ann Surg. 2017; 266: 693-701https://doi.org/10.1097/SLA.0000000000002360
- Prognostic nomograms for prediction of recurrence and survival after curative liver resection for hepatocellular carcinoma.Ann Surg. 2015; 261: 939-946https://doi.org/10.1097/SLA.0000000000000747
- IMbrave150 investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.N Engl J Med. 2020; 382: 1894-1905https://doi.org/10.1056/NEJMoa1915745
- Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.N Engl J Med. 1996; 334: 693-699https://doi.org/10.1056/NEJM199603143341104
- Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria.Gastroenterology. 2012; 143: 985-986https://doi.org/10.1053/j.gastro.2012.05.052
- Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: a prospective validation.Hepatology. 2015; 62: 158-165https://doi.org/10.1002/hep.27787
- Metroticket 2.0 model for analysis of competing risks of death following liver transplantation for hepatocellular carcinoma.Gastroenterology. 2018; 154: 128-139https://doi.org/10.1053/j.gastro.2017.09.025
Published online: August 11, 2021
Accepted: August 9, 2021
Received in revised form: July 19, 2021
Received: June 2, 2021
© 2021 Elsevier Inc. All rights reserved.